Leveraging Technology to Cut Through the REMS Confusion
The Risk Evaluation and Mitigation Strategies (REMS) program has taken center stage recently as the Food and Drug Administration (FDA), pharmacies and healthcare providers seek ways to improve and streamline its administration. Created in 2007 as part of the FDA Amendments Act, REMS was designed to ensure that the benefits of a drug or biological product outweigh its risks, as well as for post-marketing surveillance of medication safety. While providers agree with these goals, many are also concerned with issues they believe are preventing REMS from achieving its objectives.
You may also like:
NCPDP, the standards development organization focused on the pharmacy sector, just wrapped up its annual business and technology conference, which immediately followed its quarterly technical ...
Opioid analgesics remain the first-line treatment for moderate-to-severe acute pain in emergency departments. But a study published in JAMA 2017 showed tha...
While studies confirm that prescription drug monitoring programs (PDMPs) do help states reduce misuse and diversion of opioid drug products, many professionals and research data still report variable benefits, inconsistent usag...
Stay in the Know
Sign up to start receiving notifications via email of our upcoming webinars!